Molecular modeling and synthesis of novel benzimidazole-derived thiazolidinone bearing chalcone derivatives: A promising approach to develop potential anti-diabetic agents

• Published in: Zeitschrift fur Naturforschung - Section C Journal of Biosciences
• Main Author: Abbasi S.A.; Rehman W.; Rahim F.; Hussain R.; Hawsawi M.B.; Alluhaibi M.S.; Alharbi M.; Taha M.; Khan S.; Rasheed L.; Wadood A.; Ali Shah S.A.
• Format: Article
• Language: English
• Published: Walter de Gruyter GmbH 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85209950182&doi=10.1515%2fznc-2024-0202&partnerID=40&md5=2713438e3ad3bfd466826e5cf5d864ca

Diabetes mellitus (DM) is a disorder which is raised at the alarming level and it is characterized by the hyperglycemia results from the impaired action of insulin, production of insulin or both of these simultaneously. Consequently, it causes problems or failure of different body organs such as kidneys, heart, eyes, nerve system. Since this disease cannot be completely cured until now, we aimed to design series of enzymes inhibitors and tested them for DM treatment. In this series, benzimidazole-based thiazolidinone bearing chalcone derivatives completed in a four step reaction and their structures were confirmed through various spectroscopic techniques. A significant efficacy on antidiabetic enzymes was observed, with IC50 values ranging from 25.05 ± 0.04 to 56.08 ± 0.07 μM for α-Amylase and 22.07 ± 0.02 to 53.06 ± 0.07 μM for α-glucosidase. The obtained results were compared to those of the standard glimepiride drug (IC50 = 18.05 ± 0.07 μM for α-Amylase and IC50 = 15.02 ± 0.03 μM for α-glucosidase). The synthesized compounds showed promising antidiabetic potency. Moreover, a molecular docking study was conducted on the most active analogs of the compounds to better understand their interactions with the active sites of the targeted enzymes. © 2024 Walter de Gruyter GmbH, Berlin/Boston 2024.